Good afternoon, everyone, and thank you for joining us today. 2024 capped another year of strong execution at Amgen. Our operations teams supplied every patient every time. Our clinical teams ...

My name is Julianne, and I will be your conference facilitator today for Amgen's fourth quarter and full year 2024 financial results conference call. All lines have been placed on mute to prevent ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Over to you, Bob. Good afternoon, everyone, and thank you for joining us today. 2024 capped another year of strong execution at Amgen. Our operations teams supplied every patient every time. Our ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Amgen's revenue has gained yearly from 2015 to 2024, except for slight declines in 2017 and 2019. Amgen is growing organically because of its own R&D and pipeline. The firm has a strong presence ...

* The known adjustments are presented net of their related tax impact, which amount to approximately $1.54 per share. (a) The adjustments include noncash amortization of intangible assets and fair ...

Amgen Inc. (NASDAQ: AMGN) stock is down about 1.4% in after-hours trading despite beating estimates on the top and bottom lines in its fourth quarter 2024 earnings report. Investors appear to be ...

Dividend: $2.25 per share in the fourth quarter, a 6% increase from 2023. Amgen Inc (NASDAQ:AMGN) reported a 19% year-over-year increase in total revenues for 2024, driven by strong product sales ...

In November, architects, designers, digital fabricators, and innovators gathered in Calgary, Canada, for the 2024 Association for Computer Aided Design in Architecture (ACADIA) conference.

For the full year 2024, Amgen's total revenues increased 19% to $33.4 billion compared to 2023. Product sales grew 19%, driven by 23% volume growth, partially offset by 2% lower net selling price.

Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024 ...